13-Mar-2025 3:01 PM CST - Business Wire Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the fourth quarter and year ended December 31, 2024, and provided a business update. As we close the book on 2024 and embrace the promise of 2
7-Nov-2024 3:03 PM CST - Business Wire Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the third quarter ended September 30, 2024 and provided a business update. Looking forward, we expect 2025 to be an exceptionally important year for
13-Mar-2025 3:01 PM CST - Business Wire Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the fourth quarter and year ended December 31, 2024, and provided a business update. As we close the book on 2024 and embrace the promise of 2
7-Nov-2024 3:03 PM CST - Business Wire Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the third quarter ended September 30, 2024 and provided a business update. Looking forward, we expect 2025 to be an exceptionally important year for
